Determination of Paracetamol and Orphenadrine Citrate in Tablets via a Novel RP-HPLC Method: Development Following Box–Behnken Design, Validation, Robustness Testing, and Greenness Assessment

Paracetamol (PAR) and orphenadrine citrate (ORPH) are two active substances commonly used in combination medicinal products, due to the analgesic effect of paracetamol and the muscle relaxant effect of orphenadrine, with a therapeutic indication of mild to moderate acute musculoskeletal pain. The aim of this work is to develop and validate an isocratic HPLC method for the simultaneous determination of PAR and ORPH in tablet formulation. Preliminary experiments showed that an analytical column with a chemically bound phenyl phase was required. A Box–Behnken design (BBD) was utilized to optimize the analytical method for two key responses, PAR asymmetry factor (AsymPAR) and ORPH capacity factor (kORPH), with three numerical factors: percentage of ACN in mobile phase (A); pH (B); and salt concentration in the aqueous solution (C). The optimized method consists of a Pinnacle DB Biphenyl (250 × 4.6 mm) 5 µm column, and a mobile phase of 37%/63% v/v ACN-NaH2PO4·H2O in 29 mM aqueous solution, pH = 2.5. The flow rate was set to 1.5 mL/min and detection occurred at 215 nm. After the optimization process the following chromatographic conditions were selected and the method was validated for various ICH parameters covering system suitability, specificity, linearity (R2 = 1.00), precision (%RSD ≤ 2), accuracy (98% ≤ %Recovery ≤ 102%), and robustness. Finally, the environmental friendliness of the novel method was assessed by using the Analytical GREEnness (AGREE) metric tool, obtaining a score of 0.67.